BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2009;15:1837-1843. [PMID: 19462426 DOI: 10.1002/ibd.20974] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
2 Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis: Combination therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1177-85. [DOI: 10.1111/jgh.12517] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
3 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 256] [Article Influence: 21.9] [Reference Citation Analysis]
4 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
5 Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab. Adv Ther 2016;33:1947-63. [PMID: 27664107 DOI: 10.1007/s12325-016-0406-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. Journal of Crohn's and Colitis 2012;6:143-53. [DOI: 10.1016/j.crohns.2011.07.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
7 Cheng J, Hamilton Z, Smyth M, Barker C, Israel D, Jacobson K. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:1762-73. [DOI: 10.1097/mib.0000000000001212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Elias ED, Targownik LE, Singh H, Bernstein CN. A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflamm Bowel Dis 2020;26:150-7. [PMID: 31340002 DOI: 10.1093/ibd/izz148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther 2015;41:429-37. [PMID: 25511905 DOI: 10.1111/apt.13057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
10 Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606-613. [PMID: 24552827 DOI: 10.1097/mib.0000000000000003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
11 Ananthakrishnan AN, Binion DG. Editorial: improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: strike while the iron is hot with anti-TNF agents? Am J Gastroenterol. 2010;105:1583-1585. [PMID: 20606661 DOI: 10.1038/ajg.2010.98] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wang YM, Fang L, Zhou L, Wang J, Ahn HY. A survey of applications of biological products for drug interference of immunogenicity assays. Pharm Res 2012;29:3384-92. [PMID: 22903525 DOI: 10.1007/s11095-012-0833-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
13 Ono Y, Hirai F, Matsui T, Beppu T, Yano Y, Takatsu N, Takaki Y, Nagahama T, Hisabe T, Yao K. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn’s disease. Dig Endosc. 2012;24:432-438. [PMID: 23078435 DOI: 10.1111/j.1443-1661.2012.01315.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
14 Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci 2012;57:472-80. [PMID: 21909990 DOI: 10.1007/s10620-011-1896-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
15 Anderson AJ, Click B, Ramos-Rivers C, Babichenko D, Koutroubakis IE, Hartman DJ, Hashash JG, Schwartz M, Swoger J, Barrie AM 3rd, Dunn MA, Regueiro M, Binion DG. Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. Dig Dis Sci. 2016;61:3236-3245. [PMID: 27619390 DOI: 10.1007/s10620-016-4278-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]